No headlines found.
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
Globe Newswire (Mon, 20-Oct 7:07 PM ET)
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Novabay Pharmaceuticals trades on the AMEX stock market under the symbol NBY.
As of January 6, 2026, NBY stock price declined to $6.64 with 256,153 million shares trading.
NBY has a beta of 0.67, meaning it tends to be less sensitive to market movements. NBY has a correlation of 0.01 to the broad based SPY ETF.
NBY has a market cap of $836.71 million. This is considered a Small Cap stock.
In the last 3 years, NBY traded as high as $7.30 and as low as $.07.
The top ETF exchange traded funds that NBY belongs to (by Net Assets): VXF.
NBY has outperformed the market in the last year with a price return of +1234.2% while the SPY ETF gained +17.9%. NBY has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +388.2% and +22.3%, respectively, while the SPY returned +3.5% and +0.9%, respectively.
NBY support price is $5.65 and resistance is $7.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBY shares will trade within this expected range on the day.
